GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

Scientists at a university in the UK are in the midst of creating a breakthrough vaccine that could stop cancer in its tracks ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

The European Union's press release distribution & newswire service ...

GSK PLC GSK shares shed 2.82% to £12.94 Tuesday, on what proved to be an all-around rough trading session for the stock ...